TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma.

Will HarrisEdward J BataillardYoonha ChoiTarec C El-GalalyVaikunth CuchelkarCarsten HennegesAntonia KwanDaniel J SchneiderJoseph N PaulsonTina G Nielsen

Published in: JCO clinical cancer informatics (2022)

TRAIL may be useful as a clinical decision support tool for treatment decisions in patients with DLBCL who may not tolerate standard chemoimmunotherapies.

Keyphrases

diffuse large b cell lymphoma
clinical decision support
epstein barr virus
electronic health record
open label
clinical trial
combination therapy